About Pneumococcal Disease and Its Prevention
Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen.
TechNavio's analysts forecast the Global Pneumococcal Vaccines market to grow at a CAGR of 4.90 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Pneumococcal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines administered to actively immunize pneumococcal disease caused by different serogroups of Streptococcus pneumonia.
TechNavio's report, the Global Pneumococcal Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pneumococcal Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• GlaxoSmithKline
• Merck
• Pfizer
Other Prominent Vendors
• Lupin
• Sanofi Pasteur MSD
• S K Chemicals
Market Driver
• Included Vaccine in National Immunization Schedule
• For a full, detailed list, view our report
Market Challenge
• Inadequate Coverage of Vaccine
• For a full, detailed list, view our report
Market Trend
• Increase in Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Product Type
07.1 Polysaccharide Vaccines
07.2 Conjugate Vaccines
08. Market Assessment of Top Pneumococcal Vaccines
08.1 Synflorix
08.2 Pneumovax 23
08.3 Prevnar
09. Geographical Segmentation
09.1 Pneumococcal Vaccines Market in the US 2013-2018
09.1.1 Market Size and Forecast
10. Rate of Incidence and Prevalence
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 GlaxoSmithKline
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Sales by Geography
19.1.6 Pipeline Products
19.1.7 Business Strategy
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Merck
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue 2013
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Developments
19.2.8 SWOT Analysis
19.3 Pfizer
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pneumococcal Vaccines Market 2013-2018 (US$ million)
Exhibit 3: Global Pneumococcal Vaccines Market Segmentation by Product Type
Exhibit 4: Global Pneumococcal Vaccines Market Segmentation by Product Type 2013
Exhibit 5: Sales Comparison of Synflorix 2009-2013 (US$ million)
Exhibit 6: Region-wise Sales Comparison of Synflorix 2009-2013 (US$ million)
Exhibit 7: Sales Comparison of Synflorix in Europe 2009-2013 (US$ million)
Exhibit 8: Sales Comparison of Synflorix in EMAP 2010-2013 (US$ million)
Exhibit 9: Sales Comparison of Synflorix in ROW 2009-2013 (US$ million)
Exhibit 10: Global Sales Comparison of Pneumovax 2007-2013 (US$ milion)
Exhibit 11: Sales Comparison of Prevnar Family 2009-2013 (US$ million)
Exhibit 12: Sales Forecast of Prevnar 13 2014-2020 (in US$ billion)
Exhibit 13: Sales Comparison of Prevnar Family 2009-2013 (US$ million)
Exhibit 14: Global Pneumococcal Vaccines Market by Geographical Segmentation 2013
Exhibit 15: Pneumococcal Vaccines Market in the US 2013-2018 (US$ million)
Exhibit 16: Incidence of Childhood Clinical Pneumonia 2008
Exhibit 17: Global Pneumococcal Vaccines Market Share Analysis 2013
Exhibit 18: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 19: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 20: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 21: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 25: Pfizer Inc.: Business Segmentation
Exhibit 26: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 27: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 28: Pfizer Inc.: Revenue by Geography 2013
